Sorted By:


Pat Scannon, Xoma

From Hope To Cures  |  From Our Network


How drug importation schemes could increase U.S. law enforcement burdens

PhRMA  |  Blog Post

Criminals actively look to skirt law enforcement by mislabeling products and the like.

Medicare Monday: 3 reasons why repealing Part D’s noninterference clause is a bad idea

PhRMA  |  Blog Post

Such proposals overlook the way the program currently works and how substantial negotiation is helping keep costs low for beneficiaries.

Closing the Gap: Increasing Global Competition to Attract and Grow the Biopharmaceutical Sector

PhRMA  |  Report

The biopharmaceutical industry’s economic benefit in the United States is amplified by its large-scale supply chain for research and development (R&D), manufacturing, and distribution activities.

Chart Pack: Biopharmaceuticals in Perspective

PhRMA  |  Report

Topics include medicines’ impact on health and quality of life, the drug discovery and development process, health care spending and costs, the challenges of addressing treatment gaps and improving the use of prescribed therapies, and the contributions of the biopharmaceutical sector.

Significant progress fighting cancer: Death rate has dropped 25 percent

PhRMA  |  Blog Post

Research from a recent trial has demonstrated that 40 percent of patients are surviving three years or longer.

Part D

PhRMA  |  From PhRMA

For 2016, there are, on average, 26 Part D plan choices available in every region.

Value-Based Contracting for Oncology Drugs: A NEHI White Paper

PhRMA  |  Report

This white paper from the Network for Excellence in Health Innovation (NEHI) outlines barriers to these outcomes-based contracts and highlights regulatory steps that would enable new payment arrangements for high-cost cancer treatments.

World AIDS Day 2016: A decade of scientific innovation

PhRMA  |  Blog Post

Advances in science, with the support of America’s biopharmaceutical research companies are paving the way for better outcomes for those living with HIV.

Australia is making it harder to protect inventions. That’s bad for American businesses and jobs.

PhRMA  |  Blog Post

Or they can risk a massive financial penalty that equates legitimate enforcement with patent abuse.

Coverage Gap Phaseout, to Date, Has Improved Medication Adherence for Diabetes

Chartpack  |  From Our Network

Research shows that the phaseout of the coverage gap is making medicines more affordable in the gap and has resulted in patients adhering better to prescribed therapies.

Un informe describe diversos medicamentos nuevos en desarrollo para combatir la epidemia de diabetes que afecta a más de 30 millones de estadounidenses

PhRMA  |  Press Release

Aquí puede descargar el informe completo de “Medicamentos en desarrollo para la diabetes”.

Putting the bio in biotech: How Bay Area minds are powering biopharmaceutical innovation

PhRMA  |  Blog Post

There’s no denying that the talented individuals working within the Bay Area will be at the forefront of game-changing discoveries in our industry, transforming the innovation pipeline as we know it.

Former law enforcement officials raise concerns with drug importation proposals

PhRMA  |  Blog Post

If the Sanders drug importation bill is passed, the dead may soon include patients who thought they were taking legitimate drugs for legal purposes.”

RA medicines often demonstrate far greater benefits to patients than initially understood

PhRMA  |  Blog Post

Unlike the Institute for Clinical and Economic Review, which recently undertook an assessment of RA treatments, we need approaches to value assessments that can keep pace with changes in research and treatment options over time.

Executive Assistant – Law Department

PhRMA  |  PhRMA Career

Send resume and salary requirement for consideration to:

Medicare Monday: CMS withdraws Part B demo, takes positive step forward on CMMI

PhRMA  |  Blog Post

Before issuing any new demos, CMMI should carefully consider the feedback received as part of this process.

4 things to think about when choosing your health plan

PhRMA  |  Blog Post

Quick tip: Check whether your medicines are part of your health plan’s formulary and if they would require extra steps before you receive them as step therapy and prior authorizations can often be time consuming, potentially causing delays in access to needed treatments.

Phaseout of Coverage Gap in Part D Began in 2011

Chartpack  |  From Our Network

Beginning in 2011, beneficiaries receive a 50% discount on brand drugs while in the coverage gap, at a cost to brand manufacturers of $41 billion over 10 years (2012-2021).

PPA Celebrates Fourth Anniversary Has Helped More Than 5.7 Million Uninsured Patients

PhRMA  |  Press Release

It only takes 10 to 15 minutes to find out if someone may qualify for free or discounted medications.

As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority

PhRMA  |  Blog Post

As part of its effort to modernize NAFTA, the U.S. should seek to ensure stronger enforcement of patentability standards and the provisions that protect the IP of U.S. innovators, as well as address potentially negative price-setting measures.

PhRMA Convenes Stakeholders to Discuss Value Assessments and New Ways to Pay for Medicines

PhRMA  |  Press Release

The platform can be viewed online here:

Discovery of counterfeit hepatitis C drug is another example of why importation is bad for patients

PhRMA  |  Blog Post

Learn more about why drug importation is bad for patients here.

PPA: More than just prescription assistance

PhRMA  |  Blog Post

PPA Video PPA Brochure

Las Compañías Biofarmacéuticas de Estados Unidos Lanzan una Innovadora Iniciativa Anunciando la Nueva Era de la Medicina

PhRMA  |  Press Release

Desde el año 2000, las empresas miembros de PhRMA han invertido más de medio trillón de dólares en la búsqueda de nuevos tratamientos y curas, incluyendo un estimado de $58.8 mil millones en el año 2015 por sí solo.

You have reviewed the first 50 results out of 2166. Each page contains 25 results. You're on page 2.

prev 1 2 3 4 5 6 next